255 / 320
659
JD, Thorell EA, et al. Considerations in the pharmacologic treatment
and prevention of neonatal sepsis. Paediatr Drugs. 2014;16:67–
81.
23. Young TE. Therapeutic drug monitoring--the appropriate use of
drug level measurement in the care of the neonate. Clin Perinatol.
2012;39(1):25–31.
24. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug
interactions. Curr Clin Pharmacol. 2006;1:5–20.
25. Morales-Olivas FJ, Estañ L. [Drug-drug interactions. An update].
Med clínica [Internet]. 2006;127:269–75.
26. Anderson GD, Lynn AM. Optimizing pediatric dosing: a
developmental pharmacologic approach. Pharmacotherapy.
2009;29:680–90.
27. Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology:
extensive interindividual variability despite limited size. J Pediatr
Pharmacol Ther. 2011;16:170–84.
28. Johnson PN, Miller JL, Hagemann TM. Sedation and analgesia in
critically ill children. AACN Adv Crit Care. 2012;23:415–34.
29. Yee DL, O’Brien SH, Young G. Pharmacokinetics and
pharmacodynamics of anticoagulants in paediatric patients. Clin
Pharmacokinet. 2013;52:967–80.
30. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and
bone health. Arch Dis Child. 2002;87:93–6.
31. Cohlan SQ, Bevelander G, Tiamsic T, Rall DP, Milch RA, Milch RA, et
al. Growth Inhibition of Prematures Receiving Tetracycline. Am J Dis
Child. 1963;105:453-461.
32. Patel K, Goldman JL. Safety Concerns Surrounding Quinolone Use
in Children. J Clin Pharmacol. 2016; doi: 10.1002/jcph.715.
[Epub ahead of print]
33. Roberts J, Lipman J. Pharmacokinetic issues for antibiotics in the
critically ill patient. Crit Care Med. 2009;37:840–51.
34. Udy A, Roberts J, Boots RJ, Paterson DL, Lipman J. Augmented renal
clearance: implications for antibacterial dosing in the critically ill.
Clin Pharmacokinet. 2010;49:1–16.
35. Lortholary O, Lefort A, Tod M, Chomat A, Darras-joly C, Cordonnier
C, et al. Pharmacodynamics and pharmacokinetics of antibacterial
drugs in the management of febrile neutropenia. Lancet Infect Dis.
2008;8:612–20.
36. Kremer TM, Zwerdling RG, Michelson PH, O’Sullivan P. Intensive
care management of the patient with cystic fibrosis. J Intensive
Care Med. 2008;23:159–77.
37. Assadi F, Sharbaf FG. Practical considerations to drug dosing in
children with acute kidney injury. J Clin Pharmacol. 2016;56:399–
407.
38. Kendrick JG, Carr RR, Ensom MHH. Pediatric Obesity:
Pharmacokinetics and Implications for Drug Dosing. Clin Ther.
2015;37:1897–923.
39. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential
drug-drug interactions in infant, child, and adolescent patients in
children’s hospitals. Pediatrics. 2015;135:e99–108.
40. Siddiqi A, Khan DA, Khan FA, Razzaq A. Therapeutic drug
monitoring of amikacin in preterm and term infants. Singapore
Med J. 2009;50:486–9.
41. Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates.
Arch Dis Child. 2016;101:377–81.
42. Morales-Carpi C, Julve Chover N, Carpi Lobatón R, Estañ L,
Rubio E, Lurbe E, et al. Medicamentos utilizados en pediatría
extrahospitalaria: ¿disponemos de información suficiente? An
Pediatría. 2008;68:439–46.
43. Viada C, Ballagas C, Blanco Y. Ética en la investigación con
poblaciones especiales. Rev Cuba Invest Biomed. 2001;20:140–9.
44. Benjamin DK, Smith PB, Murphy MD, Roberts R, Mathis L, Avant
D, et al. Peer-reviewed publication of clinical trials completed for
pediatric exclusivity. JAMA. 2006;296:1266–73.
45. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, et
al. Improving Pediatric Dosing Through Pediatric Initiatives: What
We Have Learned. Pediatrics. 2008;121:530–9.
46. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed
medicine use and adverse drug reactions in children: a narrative
review of the literature. Eur J Clin Pharmacol. 2012;68:21–8.
47. Choonara I, Conroy S. Unlicensed and off-label drug use in children:
implications for safety. Drug Saf. 2002;25(1):1–5.
48. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin
Pharmacol Ther. 2012;91:796–801.
49. Milne C-P, Bruss JB. The economics of pediatric formulation
development for off-patent drugs. Clin Ther. 2008;30:2133–45.
50. Nahata MC, Allen L V. Extemporaneous drug formulations. Clin
Ther. 2008;30:2112–9.
51. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug
reactions and off-label and unlicensed medicines in children: a
prospective cohort study of unplanned admissions to a paediatric
hospital. Br J Clin Pharmacol. 2014;77:545–53.
52. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher
W, et al. The impact of unlicensed and off-label drug use on adverse
drug reactions in paediatric patients. Drug Saf. 2004;27:1059–
67.
53. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in
newborns, infants and toddlers: pediatric pharmacovigilance
between present and future. Expert Opin Drug Saf. 2012;11:95–
105.
54. Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety:
need for more efficient clinical translation of pharmacovigilance
knowledge. J Popul Ther Clin Pharmacol. 2011;18:e76–88.
55. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C,
Bonati M. Incidence of adverse drug reactions in paediatric in/
out-patients: a systematic review andmeta-analysis of prospective
studies. Br J Clin Pharmacol. 2001;52:77–83.
56. Aagaard L, Christensen A, Hansen EH. Information about adverse
drug reactions reported in children: a qualitative review of
empirical studies. Br J Clin Pharmacol. 2010;70:481–91.
57. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R,
et al. Adverse drug reactions in children--a systematic review. PLoS
One. 2012;7:e24061.
58. Star K, Edwards IR. Pharmacovigilance for children’s sake. Drug Saf.
2014;37:91–8.
59. González-Martin G, Caroca CM, Paris E. Adverse drug reactions
(ADRs) in hospitalized pediatric patients. A prospective study. Int J
Clin Pharmacol Ther. 1998;36:530–3.
[FARMACOLOGÍA DEL PACIENTE PEDIÁTRICO - Q.F. Claudio González]